vTv Therapeutics’ (VTVT) Buy Rating Reiterated at BTIG Research

vTv Therapeutics (NASDAQ:VTVT)‘s stock had its “buy” rating reiterated by equities researchers at BTIG Research in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $57.00 target price on the biotechnology company’s stock. BTIG Research’s price objective would suggest a potential upside of 106.60% from the company’s current price.

Several other research analysts have also recently issued reports on VTVT. Weiss Ratings cut vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Lifesci Capital raised shares of vTv Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 2nd. Rodman & Renshaw assumed coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price objective on the stock. Zacks Research raised shares of vTv Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. Finally, Wall Street Zen upgraded shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.83.

vTv Therapeutics Stock Up 0.3%

VTVT traded up $0.07 during mid-day trading on Wednesday, reaching $27.59. 22,240 shares of the company traded hands, compared to its average volume of 53,367. The company’s fifty day moving average price is $31.76 and its 200-day moving average price is $33.48. The stock has a market capitalization of $108.68 million, a P/E ratio of -26.03 and a beta of 0.21. vTv Therapeutics has a 52-week low of $19.50 and a 52-week high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). As a group, sell-side analysts forecast that vTv Therapeutics will post -2.35 earnings per share for the current fiscal year.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.

vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.